If you're looking for foundationmedicine.com.com's Adword's Competitors iSpionage Competitor Research is the right product for you
Top Competitors for foundationmedicine.com
| PPC Budget | # Keywords | # Overlap kw | ||
|---|---|---|---|---|
| color.com | $942 | 562 | 7 | Learn More |
| cancercenter.com | $59,344 | 16,970 | 5 | Learn More |
| prescriptiontreatmentwebsite | $784,154 | 110,530 | 5 | Learn More |
| invitae.com | $3,521 | 371 | 4 | Learn More |
| helix.com | $1,732 | 1,365 | 4 | Learn More |
Competitor offers & landing pages
Sample SEO Keywords for: foundationmedicine.com
Organic Listings | 1st Page Keywords | Avg Pos | Pos Trend | Est.Traffic | Traffic Value | |
|---|---|---|---|---|---|---|
FoundationOne Liquid - Foundation Medicine https://www.foundationmedicineFoundationOne Liquid is our ne | 7 | 6 ( 9 ) | 220 | $323 | ||
| Keyword | Position | Trend | Search Vol | CPC | ||
| www foundation com | 15 | 20 | $1.68 | |||
| foundation test | 3 ( 5 ) | 40 | $2.57 | |||
| liquid cancer | 9 | 70 | $8.83 | |||
| free medicine foundation | 16 | 40 | $2.03 | |||
| liquid testing | 19 | 0 | N /A | |||
Genomic Testing | Foundation Medicine https://www.foundationmedicineOur tests provide information | 12 | 10.21 ( 2.66 ) | 1420 | $51 | ||
| Keyword | Position | Trend | Search Vol | CPC | ||
| foundation medical | 5.5 | 260 | $5.67 | |||
| profile testing | 9 ( 4 ) | 10 | $2.47 | |||
| tumor testing | 16 ( 3 ) | 20 | $11.75 | |||
| genome testing for cancer | 21 ( 6.5 ) | 20 | $5.55 | |||
| foundation test | 7 | 40 | $2.57 | |||
Sample PPC Keywords for: foundationmedicine.com
Top Ads
Minimally-Invasive Cancer Test - From a Simple Blood Draw Convenient, Reliable Insights to Guide Cancer Care When Tissue Isn't Sufficient. Trusted Genomic Insights. Inform Clinical Decisions. Reports MSI-H. HRD Resistance Genes. More Options for Patients. Li www.foundationmedicine.com/liquid Order a Test Convenient, Reliable Insights to Guide Cancer Care When Tissue Isn't Sufficient. Inform Clinical Decisions. IO Resistance Genes. More Options for Patients. Trusted Genomic Insights. Liquid Biopsy Test www.foundationmedicine.com/liquid F1CDx Biomarker Testing - See Ovarian Cancer Details 1st FDA-Approved Comprehensive Genomic Profiling Test for Solid Tumors. Reports MSI-H. Personalizing Cancer Care. Comprehensive Gene List. Precision Medicine. Trusted Genomic Insights. Inform Clinical www.foundationmedicine.com/F1CDx Foundation Medicine - FDA-Approved Biomarker Testing Next-Gen Sequencing Can Help Identify More Therapy Options for Patients. 324 Genes Tested. Reports MSI-H. Personalizing Cancer Care. Precision Medicine. 17 FDA-Approved Therapies. Trusted Genomic Insi www.foundationmedicine.com/F1CDx | |||
Foundation Medicine - FDA-Approved Biomarker Testing Next-Gen Sequencing Can Help Identify More Therapy Options for Patients. Inform Clinical Decisions. 17 FDA-Approved Therapies. Personalizing Cancer Care. 324 Genes Tested. Trusted Genomic Insights. Co www.foundationmedicine.com/F1CDx FoundationOne®Liquid - Minimally-Invasive Cancer Test Liquid Test, Solid Answers. A Simple Blood Draw Can Deliver Actionable Results. Reports MSI-H. Inform Clinical Decisions. Personalizing Cancer Care. More Options for Patients. HRD Resistance Genes. Tr www.foundationmedicine.com/liquid Rucaparib? - Try Next Generation Sequencing 1st FDA-Approved Comprehensive Genomic Profiling Test for Solid Tumors. Precision Medicine. Personalizing Cancer Care. Trusted Genomic Insights. Immunotherapy Biomarkers. 324 Genes Tested. More Option www.foundationmedicine.com/F1CDx See the FDA-Approved F1CDx - For Genomic Testing in 2018 The First FDA-Approved Comprehensive Genomic Profiling Test for Solid Tumors. Comprehensive Gene List. Reports MSI-H. More Options for Patients. Immunotherapy Biomarkers. Personalizing Cancer Care. 17 www.foundationmedicine.com/F1CDx | |||
Foundation Medicine - FDA-Approved Biomarker Testing Next-Gen Sequencing Can Help Identify More Therapy Options for Patients. 17 FDA-Approved Therapies. Comprehensive Gene List. More Options for Patients. Inform Clinical Decisions. 324 Genes Tested. Imm www.foundationmedicine.com/F1CDx FoundationOne®Liquid - Quality Is In Our Blood Comprehensive Genomic Testing, Regardless of Tissue Status. Learn More Today. Minimally-Invasive. www.foundationmedicine.com/liquid FoundationOne®CDx - Broad Companion Diagnostic FDA-Approved Genomic Testing for NSCLC, Colorectal, Prostate & Other Cancers. 324 Genes Tested. Trusted Genomic Insights. Comprehensive Gene List. Immunotherapy Biomarkers. Personalizing Cancer Care. www.foundationmedicine.com/F1CDx FoundationOne®CDx - Solid Tumor Biomarker Testing Next-Gen Sequencing Can Help Identify More Therapy Options for Patients. Trusted Genomic Insights. Inform Clinical Decisions. More Options for Patients. Comprehensive Gene List. www.foundationmedicine.com/F1CDx | |||
How to Order a Test Results Include Microsatellite Instability & Tumor Mutational Burden. See More. Precision Medicine. www.foundationmedicine.com/F1CDx FoundationOne®CDx - Broad Companion Diagnostic FDA-Approved Genomic Testing for NSCLC, Colorectal, Prostate & Other Cancers. Trusted Genomic Insights. Reports MSI-H. 17 FDA-Approved Therapies. 324 Genes Tested. Next-Gen Sequencing. Comprehensive G www.foundationmedicine.com/F1CDx F1CDx, FDA-Approved - Next-Gen Sequencing in 2018 The First FDA-Approved Comprehensive Genomic Profiling Test for Solid Tumors. Personalizing Cancer Care. Comprehensive Gene List. Reports MSI-H. Inform Clinical Decisions. 324 Genes Tested. More Optio www.foundationmedicine.com/F1CDx Genomic Testing Next-Gen Sequencing Can Help Identify More Therapy Options for Patients. Personalizing Cancer Care. Reports MSI-H. More Options for Patients. 17 FDA-Approved Therapies. Precision Medicine. www.foundationmedicine.com/F1CDx | |||
Minimally-Invasive Cancer Test - From a Simple Blood Draw Convenient, Reliable Insights to Guide Cancer Care When Tissue Isn't Sufficient. Reports MSI-H. Personalizing Cancer Care. Liquid Biopsy Test. Trusted Genomic Insights. IO Resistance Genes. HRD Resist www.foundationmedicine.com/liquid Minimally-Invasive Cancer Test - From a Simple Blood Draw Convenient, Reliable Insights to Guide Cancer Care When Tissue Isn't Sufficient. Personalizing Cancer Care. IO Resistance Genes. Inform Clinical Decisions. More Options for Patients. Reports MSI-H. Tr www.foundationmedicine.com/liquid See the FDA-Approved F1CDx - For Genomic Testing in 2018 The First FDA-Approved Comprehensive Genomic Profiling Test for Solid Tumors. Comprehensive Gene List. More Options for Patients. 17 FDA-Approved Therapies. Next-Gen Sequencing. 324 Genes Tested. Info www.foundationmedicine.com/F1CDx FoundationOne®CDx - Solid Tumor Biomarker Testing Next-Gen Sequencing Can Help Identify More Therapy Options for Patients. Reports MSI-H. Precision Medicine. Inform Clinical Decisions. Comprehensive Gene List. Trusted Genomic Insights. Immunotherapy www.foundationmedicine.com/F1CDx | |||
FoundationOne®CDx From FMI - FDA-Approved Biomarker Test The First FDA-Approved Comprehensive Genomic Profiling Test for Solid Tumors. Reports MSI-H. www.foundationmedicine.com/F1CDx Biomarker Testing in 2018 - FoundationOne®CDx Results Include Microsatellite Instability & Tumor Mutational Burden. See More. Reports MSI-H. 324 Genes Tested. More Options for Patients. Inform Clinical Decisions. Precision Medicine. 17 FDA-Approv www.foundationmedicine.com/F1CDx F1CDx, FDA-Approved - Next-Gen Sequencing in 2018 The First FDA-Approved Comprehensive Genomic Profiling Test for Solid Tumors. 324 Genes Tested. www.foundationmedicine.com/F1CDx Microsatellite Instability - See the FDA-Approved F1CDx The First FDA-Approved Comprehensive Genomic Profiling Test for Solid Tumors. Trusted Genomic Insights. Comprehensive Gene List. 324 Genes Tested. Reports MSI-H. Inform Clinical Decisions. Personalizi www.foundationmedicine.com/F1CDx | |||
Genomic Testing The First FDA-Approved Comprehensive Genomic Profiling Test for Solid Tumors. Reports MSI-H. Comprehensive Gene List. Immunotherapy Biomarkers. 324 Genes Tested. Personalizing Cancer Care. Inform Clin www.foundationmedicine.com/F1CDx FoundationOne®Liquid - Minimally-Invasive Cancer Test Liquid Test, Solid Answers. A Simple Blood Draw Can Deliver Actionable Results. Liquid Biopsy Test. Reports MSI-H. Trusted Genomic Insights. HRD Resistance Genes. More Options for Patients. Personaliz www.foundationmedicine.com/liquid Order a Test Convenient, Reliable Insights to Guide Cancer Care When Tissue Isn't Sufficient. Reports MSI-H. Personalizing Cancer Care. IO Resistance Genes. Trusted Genomic Insights. Inform Clinical Decisions. Liq www.foundationmedicine.com/liquid See the FDA-Approved F1CDx - For Genomic Testing in 2018 The First FDA-Approved Comprehensive Genomic Profiling Test for Solid Tumors. Personalizing Cancer Care. Reports MSI-H. Precision Medicine. Next-Gen Sequencing. Trusted Genomic Insights. www.foundationmedicine.com/F1CDx | |||
FoundationOne®CDx - Broad Companion Diagnostic FDA-Approved Genomic Testing for NSCLC, Colorectal, Prostate & Other Cancers. Comprehensive Gene List. Reports MSI-H. Next-Gen Sequencing. 324 Genes Tested. Precision Medicine. www.foundationmedicine.com/F1CDx See the FDA-Approved F1CDx - For Genomic Testing in 2018 The First FDA-Approved Comprehensive Genomic Profiling Test for Solid Tumors. Reports MSI-H. www.foundationmedicine.com/F1CDx FDA-Approved Biomarker Test - FoundationOne®CDx From FMI The First FDA-Approved Comprehensive Genomic Profiling Test for Solid Tumors. 17 FDA-Approved Therapies. Personalizing Cancer Care. Next-Gen Sequencing. Inform Clinical Decisions. Reports MSI-H. Immun www.foundationmedicine.com/F1CDx See the FDA-Approved F1CDx - For Genomic Testing in 2018 The First FDA-Approved Comprehensive Genomic Profiling Test for Solid Tumors. Reports MSI-H. Inform Clinical Decisions. Trusted Genomic Insights. 324 Genes Tested. Immunotherapy Biomarkers. www.foundationmedicine.com/F1CDx | |||
Minimally-Invasive Cancer Test - From a Simple Blood Draw Convenient, Reliable Insights to Guide Cancer Care When Tissue Isn't Sufficient. Reports MSI-H. Liquid Biopsy Test. Personalizing Cancer Care. Trusted Genomic Insights. HRD Resistance Genes. IO Resist www.foundationmedicine.com/liquid Minimally-Invasive Cancer Test - From a Simple Blood Draw Convenient, Reliable Insights to Guide Cancer Care When Tissue Isn't Sufficient. IO Resistance Genes. HRD Resistance Genes. Personalizing Cancer Care. Reports MSI-H. www.foundationmedicine.com/liquid FDA-Approved Biomarker Test - FoundationOne®CDx From FMI The First FDA-Approved Comprehensive Genomic Profiling Test for Solid Tumors. Inform Clinical Decisions. Precision Medicine. Reports MSI-H. Personalizing Cancer Care. Trusted Genomic Insights. Immunot www.foundationmedicine.com/F1CDx FoundationOne®Liquid - Trusted by Oncologists Convenient, Reliable Insights to Guide Cancer Care When Tissue Isn't Sufficient. Reports MSI-H. www.foundationmedicine.com/liquid | |||
Foundation Medicine - FDA-Approved Biomarker Testing Next-Gen Sequencing Can Help Identify More Therapy Options for Patients. Precision Medicine. Trusted Genomic Insights. Reports MSI-H. Immunotherapy Biomarkers. 324 Genes Tested. More Options for Patie www.foundationmedicine.com/F1CDx How to Order a Test Next-Gen Sequencing Can Help Identify More Therapy Options for Patients. www.foundationmedicine.com/F1CDx See the FDA-Approved F1CDx - For Genomic Testing in 2018 The First FDA-Approved Comprehensive Genomic Profiling Test for Solid Tumors. 324 Genes Tested. Precision Medicine. More Options for Patients. Next-Gen Sequencing. Trusted Genomic Insights. Inform Cli www.foundationmedicine.com/F1CDx Minimally-Invasive Cancer Test - From a Simple Blood Draw Convenient, Reliable Insights to Guide Cancer Care When Tissue Isn't Sufficient. IO Resistance Genes. Liquid Biopsy Test. Inform Clinical Decisions. Personalizing Cancer Care. Reports MSI-H. Trusted G www.foundationmedicine.com/liquid | |||
